Evidence guide
What does the evidence show about chronic care management?
Observational Medicare studies associate chronic care management with fewer hospital admissions and acute encounters in some populations, and the CMS evaluation estimated slower Medicare spending growth and net savings after program fees. Results vary by population and analysis, so this guide matches each study to the decision it can inform. Vironix pairs CCM with RPM so readings connect to continuing care management.
Summary by Vironix Health · Source review: November 12, 2026
How we select and interpret evidence
Curation cutoff: November 12, 2026
What to take away
- CCM receipt was associated with fewer admissions in Louisiana diabetes populations, and CMS estimated $36 million in net Medicare savings after CCM fees in its early evaluation.
- Billing data show how much CCM is used, not which care patients received; track delivered care alongside enrollment.
- Selection effects and analysis choices matter: judge outcomes and savings with clear units, a stated perspective and program fees included.
Match each CCM study to the decision it can inform
Question | Relevant evidence | What it cannot establish |
|---|---|---|
How widely is CCM used, and do beneficiaries continue receiving billed services? | Jang and Annis describe beneficiary uptake and persistence (Jang) and primary-care provider billing adoption (Annis). | Adoption is not a causal test of patient benefit or profitability. |
Are patient outcomes different? | Shao and Hong report observational associations in Louisiana diabetes populations. | Confounding, mixed outcomes and potentially overlapping populations limit causal inference. |
Does Medicare spending change? | CMS evaluation separates spending before and after program fees. | Results were sensitive to survivor-only and uncapped-expenditure analyses; these are not practice-margin estimates. |
Can a reported cost reduction support our business case? | Clark reports lower costs but has conflicting units and cohort descriptions. | It does not supply a dependable annual savings figure or total payer-cost estimate. |
Supporting studies: Jieun Jang (2024) [1]; Ann Annis (2023) [2]; Yixue Shao (2023) [3]; Dongzhe Hong (2024) [4]; John Schurrer (2017) [5]; Bennett W. Clark (2026) [6]
Distinguish CCM evidence from evidence for adding CCM to RPM
Claims-based CCM studies compare billed service use and outcomes; those comparisons do not isolate the effect of adding CCM to an otherwise identical RPM program. The absence of a described monitoring component is not proof that patients received no monitoring.
Supporting studies: Yixue Shao (2023) [3]
Adoption describes payment and reach
Jang and Annis describe limited billing uptake and persistence. Clemens adds evidence that new billing codes interact with existing services: CCM and transitional-care billing correlated with more wellness billing, while transitional-care billing correlated with fewer traditional post-discharge office visits. These patterns do not demonstrate better health or net savings.
Supporting studies: Jieun Jang (2024) [1]; Ann Annis (2023) [2]; Jeffrey Clemens (2026) [7]
Keep the mixed outcomes visible
Shao’s Louisiana analysis associated CCM overall with fewer acute encounters, but complex CCM was associated with more ED use and some complication outcomes were unchanged or worse. Kadree’s small implementation used patients who declined CCM as controls and lost 23 of 84 enrollees before completion. Neither establishes a general causal effect.
Supporting studies: Yixue Shao (2023) [3]; Margaret A Kadree (2025) [8]
Hong: promising associations with selection risk
Hong’s separate Louisiana claims analysis found fewer admissions and a large mortality association. Outpatient use excluding CCM encounters did not clearly change, and stroke was inconclusive. Missing hospice, clinical and provider factors leave substantial confounding. Its population may overlap Shao’s, so these papers should not be counted as independent replications.
Supporting studies: Dongzhe Hong (2024) [4]; Yixue Shao (2023) [3]
CMS: distinguish gross, net and sensitivity analyses
The CMS report gives both a spending-growth estimate before fees and a separate aggregate estimate after paid CCM fees. However, the spending result disappeared in survivor-only and uncapped-expenditure sensitivity analyses. These qualifications matter more than using a single headline savings number.
Supporting studies: John Schurrer (2017) [5]
Clark: retain the result and its unresolved problems
Clark reports lower costs among CCM participants, but cost units, enrollment duration and model descriptions conflict. The analysis cannot establish a dependable annual savings figure or total payer-cost reduction. Including this paper makes the uncertainty visible; it does not validate its conclusions.
Supporting studies: Bennett W. Clark (2026) [6]
Evidence gaps
Most studies in this guide examine CCM services billed to Medicare. The selected evidence does not establish a universal causal reduction in mortality, hospitalizations or total spending. Some adoption data are several years older than their publication dates.
Practical interpretation
Use the evidence to discuss care goals and reporting with your CCM service partner:
- Review enrollment and billed months alongside completed contacts, care-plan work and patient outcomes.
- Agree how the managed team coordinates outreach, medication questions, specialist communication and follow-up with the practice.
- Include missed contacts and reasons for withdrawal when reviewing participation and results.
- Evaluate practice finances using collected revenue, agreed service fees and any costs the practice directly bears over the same period.
The workflow guide explains coordination with a managed team; the economic evidence guide distinguishes practice finances from payer spending. See Vironix CCM services for the delivery model. The published studies evaluate their own programs and do not assess the terms of a Vironix service agreement.
References
- Use of chronic care management service among Medicare beneficiaries in 2015–2019
Jieun Jang; Ellen P McCarthy; Brianne Olivieri-Mui; Sandra M Shi; Chan Mi Park; Gahee Oh; Stephanie Denise M Sison; Dae Hyun Kim. Journal of the American Geriatrics Society. 2024.
Original source - Utilization of Medicare's chronic care management services by primary care providers
Ann Annis; Hyokyoung G Hong. Nursing Outlook. 2023.
Original source - The Impact of Reimbursement for Non-Face-to-Face Chronic Care Management on Health Utilization Among Patients With Type 2 Diabetes in Louisiana
Yixue Shao; Charles Stoecker; Dongzhe Hong; Elizabeth Nauman; Vivian Fonseca; Gang Hu; Alessandra N Bazzano; Edmond K Kabagambe; Lizheng Shi. Value in Health. 2023.
Original source - Effects of Non-Face-to-Face Chronic Care Management on Service Utilization and Outcomes Among US Medicare Beneficiaries with Diabetes
Dongzhe Hong; Charles Stoecker; Yixue Shao; Elizabeth Nauman; Vivian Fonseca; Gang Hu; Alessandra N. Bazzano; Edmond K. Kabagambe; Lizheng Shi. Journal of General Internal Medicine. 2024.
Original source - Evaluation of the Diffusion and Impact of the Chronic Care Management (CCM) Services: Final Report
John Schurrer; Ann O'Malley; Claire Wilson; Nancy McCall; Neetu Jain. Mathematica Policy Research report for CMS. 2017.
Original source - Cost impact of chronic care management services in a large multi-specialty practice: A pragmatic outcomes study
Bennett W. Clark; Jacob Webster; Souvik Chatterjee; Michael D. Finch. PLOS One. 2026.
Original source - Plugging gaps in payment systems: Evidence from the take-up of new Medicare billing codes
Jeffrey Clemens; Jonathan M. Leganza; Alex Masucci. Contemporary Economic Policy. 2026.
Original source - Evaluation of a Chronic Care Management Model for Improving Efficiency and Fiscal Sustainability
Margaret A Kadree; Patrick Wiggins; Lura Thompson; Cynthia Warriner; Michelle White. American Journal of Public Health. 2025.
Original source
Explore Vironix services: CCM